NATIONAL VACCINE PROGRAM OFFICE

TASK FORCE ON RESEARCH SPECIFIC TO PREGNANT WOMEN AND LACTATING WOMEN (PRGLAC)

Karin Bok, PhD, MS

AUGUST 21, 2017








MATERNAL IMMUNIZATIONS RECOMMENDED BY THE CDC, BUT WITHOUT A SPECIFIC INDICATION BY FDA

Influenza: Any trimester (updated in 2004)
Tdap: every pregnancy between 27 and 36 weeks of gestation (2012)

Maternal immunizations that might become available: **RSV, GBS, CMV**

INFLUENZA VACCINATION COVERAGE DURING PREGNANCY



IMMUNIZATION DURING PREGNANCY APPROACH

- Increasing support of maternal immunization research
- Communicating and educating about maternal immunizations
- Overcoming barriers and identifying opportunities for developing additional maternal immunizations

SUPPORTING MATERNAL VACCINATION RESEARCH WITH FEDERAL PARTNERS

Leading Agency/System	Scientific Activities	
CDC/CISA	Clinical Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) Safety in Pregnant Women	
CDC/CISA	Clinical Study of the Safety of Simultaneous Administration of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (Tdap) and Inactivated Influenza Vaccine (IIV) in Pregnant Women – Pilot	
FDA/BARDA/NVPO	Analysis of the association between infections, vaccinations, and medications during pregnancy and possible birth defects outcomes, and Creation of an archived database	
CDC-VSD/OASH	Development and evaluation of novel methods to identify possible increased risks of fetal loss (spontaneous abortion and stillbirth) following vaccination in pregnancy in the Vaccine Safety Datalink	

SUPPORTING MATERNAL VACCINATION SAFETY RESEARCH WITH NON FEDERAL COLLABORATORS

Awardee: Kaiser Foundation Hospitals—Kaiser Foundation Research Institute Principal Investigator: Roger Baxter, MD and Co-Principal Investigator Nicola Klein, MD, PhD

Description: NVPO funded the creation of a maternal-neonatal vaccine safety database and analysis of outcomes using the database. The first analysis compares the likelihood of fever in babies born to vaccinated versus unvaccinated mothers after receiving their first pertussis vaccination. The second analysis compares alternative benefits of influenza vaccination during pregnancy. Published Research:

-- <u>Kaiser Permanente Northern California Pregnancy Database:</u> <u>Description and proof of concept study</u>

-- No association between influenza vaccination during pregnancy and adverse birth outcomes

SUPPORTING MATERNAL VACCINATION SAFETY RESEARCH WITH INTERNATIONAL COLLABORATORS

- Awardee: Cincinnati Children's Hospital Medical Center
 Principal Investigator: Steven Black, MD
- Description: This project aims to validate the Global Alignment of Immunization Safety Assessment in pregnancy (GAIA) maternal and neonatal outcome definitions to standardize the evaluation of the safety of vaccines.(US, Australia and UK)

EDUCATION: VACCINES.GOV

vaccines.gov your best shot at good health			Home About Contact Us Email Updates Español				
Basics	Diseases	Who & When	Getting Vaccinated	Travel	More Info		
Home > Who & When > Pregnant							
Infants, Childre	en, & Teens		Text Size: A A A	Print Tweet P	ost Send Share		
Child Catch-up age 4 mos-18	age 4 mos-18 Vaccinations during Pregnancy						
College & Your age 19-24 Adults age 19 and olde Seniors age 65 and olde	er	Vaccines can help protect both you and your baby from vaccine-preventable diseases. During pregnancy, vaccinated mothers pass on protective antibodies — infection-fighting molecules—to their babies before they are born. This provides some immunity against certain vaccine-preventable diseases during their first few months of life, when your baby is still too young to be vaccinated. It also helps provide important protection for you throughout your pregnancy.					
Pregnant		Vaccines for Pregnant Women					
Health Conditions There are two vaccines routinely recommended by CDC to be adminduring pregnancy: ■ Flu Vaccine: During each pregnancy you should get the inactive influenza (flu) vaccine (IIV) (flu shot) to protect yourself and you from the flu. It can be given during any trimester of pregnancy. A woman who gets the flu is at increased risk for serious complication.		ated r baby A pregnant					

COMMUNICATION: @HHSVACCINES



Natl Vaccine Program @HHSvaccines · 22 Sep 2016 Do you know which vaccines pregnant women need? bit.ly/1E4Glkg

Natl Vaccine Program @HHSvaccines · Aug 11 Take @CDCgov's quiz to find information about vaccines for women before, during & after pregnancy: bit.ly/2kp7zTE #NIAM17



Vaccines and Pregnancy: Take the Quiz to Learn M... Getting vaccinated is an important part of a healthy pregnancy. cdc.gov

NVPO

Natl Vaccine Program @HHSvaccines · 8 Aug 2016 2 vaccines are routinely recommended for pregnant women: TDaP & #flu. Learn more: bit.ly/1E4Glkg #NIAM2016



and pass protection on to your baby.



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PROVIDER ENGAGEMENT



Upshot Webinar Series

The Path to a World Free of Polio, Measles, and Rubella, and Remaining Risks for the United States

Tuesday, April 25 from 12 pm - 1:30 pm ET

Register now at hhs.gov/nvpo/webinars

UpShot Awards Program




For work optimizing the vaccine and immunization system



hhs.gov/nvpo/awards

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES





30 Years Optimizing Immunization

NVAC AND MATERNAL IMMUNIZATION CHALLENGES IN THE U.S.

- 1. Enrolling susceptible populations in clinical trials
- 2. Case-control studies on vaccines currently recommended for pregnant women (Flu and Tdap)
- 3. Large cohorts that will enable studying rare adverse events (birth defects)
- 4. Defining the endpoint of a vaccine safety clinical trial: creating consensus across trials nationally and globally
- 5. Liability concerns when administering vaccines recommended for pregnant women only and/or intended to protect the baby
- 6. Linking health records of pregnant women and infants to enable long-term follow-up of infant
- 7. Safety and regulatory requirements to obtain an indication specific for pregnancy

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

NVAC REPORT ON MATERNAL IMMUNIZATIONS

Reports and Recommendations

Overcoming Barriers and Identifying Opportunities for Developing Maternal Immunizations: Recommendations From the National Vaccine Advisory Committee Public Health Reports Vol. 132(3) 1-14 © 2017, Association of Schools and Programs of Public Health All rights reserved. Reprints and permission: sagepub.com/journalsPermissions.nav DOI: 10.1177/0033354917698118

journals.sagepub.com/home/phr



Approved by the National Vaccine Advisory Committee on September 20, 2016



FOCUS AREA 1: ETHICAL ISSUES

- 1.1 The ASH should work with the Office for Human Research Protections (OHRP) and other relevant stakeholders and agencies to revise the current exclusionary climate of research in pregnancy. Such areas of focus include but are not limited to:
 - 1.1.1 Institutional Review Board (IRB) guidance on interpretation of minimal risk
 - 1.1.2 Code of Federal Regulations language surrounding research in pregnancy
 - 1.1.3 Collaboration with bioethics experts, regulatory agencies, and the scientific community to optimize the design of studies to minimize the risk of interventions for research in pregnancy
 - 1.1.4 Relevant regulations, statutes, and policies that should be modified to indicate that pregnant women are not a vulnerable population for the purposes of ethical review (via update to Common Rule Subpart A)
- 1.2 The ASH should work with OHRP and the stakeholder community to develop policy and regulatory guidelines that would promote inclusion of pregnant women in clinical trials when scientifically appropriate (PGRLAC addressed in the 21st Century Cures Act)

FOCUS AREA 2: POLICY ISSUES

- 2.1 The ASH should continue to support maternal immunization as an important public health strategy to encourage manufacturer investment in the development of new and currently licensed vaccines for additional indications for use specifically in pregnant women (via 21st Century Cures Report on Vaccine Innovation)
- 2.2 The ASH should advocate to the Secretary of Health and Human Services to resolve the uncertainties around coverage under the Vaccine Injury Compensation Program (VICP) for vaccines administered to pregnant women that are not recommended for use in children by the CDC, and for liability protections for live-born infants born to mothers vaccinated during pregnancy

21ST CENTURY CURES ACT

• The Vaccine Injury Compensation Program:

- The Secretary shall revise the Vaccine Injury Table included in subsection (a), through the process described in subsection (c), to include vaccines recommended by the Centers for Disease Control and Prevention for routine administration in pregnant women and the information described in paragraphs (B) and (C) with respect to such vaccines.
- (1) IN GENERAL.—Notwithstanding any other provision of law, for purposes of this subtitle, both a woman who received a covered vaccine while pregnant and any child who was in utero at the time such woman received the vaccine shall be considered persons to whom the covered vaccine was administered and persons who received the covered vaccine. Section 2111(b)(2) of the Public Health Service Act (42 U.S.C. 300aa– 10 11(b)(2)) is amended by adding "A covered vaccine administered to a pregnant woman shall constitute more than one administration, one to the mother and one to each child (as such term is defined in subsection (f)(2)) who was in utero at the time such woman was administered the vaccine." at the end.

FOCUS AREA 3: PRE-CLINICAL AND CLINICAL RESEARCH ISSUES

- 3.1 The ASH should prioritize increased support for pre-clinical and early clinical research to understand the immune response during pregnancy and to develop vaccines for pregnant women:
 - 3.1.1 The ASH should work with federal and non-federal stakeholders to create or promote mechanisms that support investigator-initiated and other types of research that fosters innovation and expands the field of vaccines for pregnant women
- 3.2 The ASH should emphasize the need for a better understanding of the public health burden of diseases preventable by maternal immunization
- 3.3 The ASH should work with CDC, NIH, and other relevant federal agencies to support evaluation of the maternal and neonatal outcomes of vaccines administered during pregnancy with respect to the (1) safety of vaccines and (2) effectiveness of vaccines to reduce maternal and infant morbidity and mortality caused by vaccine-preventable diseases, and (3) to better understand the potential risks and benefits of maternal immunization

FOCUS AREA 3 (CONT.): PRE-CLINICAL AND CLINICAL RESEARCH ISSUES

- 3.4 The ASH should support continuing evaluation of vaccines in pregnant women and infants born to vaccinated mothers, while advocating for the adoption of standardized approaches to data collection, analysis, and safety evaluation
- 3.5 The ASH should support the adoption and utilization of standardized definitions of possible maternal and neonatal outcomes to evaluate the safety and effectiveness of vaccines administered during pregnancy
- 3.6 The ASH should convene stakeholders and other federal agencies to work on the expansion of pharmacovigilance systems that readily link maternal and infant electronic health records and safety surveillance systems

FOCUS AREA 4: PROVIDER EDUCATION AND SUPPORT ISSUES

- 4.1 The ASH should encourage professional societies to continue to support the inclusion of pregnant women in clinical research
- 4.2 The ASH should work with relevant stakeholders to increase awareness among obstetric providers and pregnant women about the importance of vaccine research during pregnancy
- 4.3 The ASH should work with professional societies to educate obstetricians and other obstetric providers on vaccination and interpretation of new regulations regarding labelling (i.e., the Pregnancy and Lactation Labeling Rule) so they can make informed decisions and counsel their patients more effectively